Clinical trial
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
NCT04144348 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, and to Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
- Lead sponsor
- ModernaTX, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 4, 2019
- Completion date
- December 20, 2022
- Enrollment
- 51 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
human metapneumovirus and human parainfluenza infection